Acquisition - August 18, 2026
LEO Pharma acquires dersimelagon rights from Tanabe
LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.
In a new job - August 4, 2026
EQL Pharma recruits new Chief Supply Chain Officer
EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO).
Business article - June 29, 2026
Open letter from ELSC calling on EU leaders to make life sciences a strategic priority
The newly formed European Life Sciences Coalition (ELSC) has sent an open letter to leading decision-makers and politicians in the EU and Sweden, urging them to take action.
Biotech Business - June 29, 2026
Cantargia announces outcome in rights issue
The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.
Uncategorized - April 29, 2026
Tortugas Neuroscience launches with USD 106 million for mid‑stage brain drugs
The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.
Biotech Business - December 9, 2025
Leqembi included in China’s commercial insurance innovative drug list
BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.
